Bacterial membrane integrity

Bacterial membrane integrity" is not a discrete molecular target but a critical property of bacterial cells referring to the intact structure and function of their plasma membrane(s)[2][3][4]. In the context of drug discovery, this term usually describes a vulnerability: many antibacterial agents exert their effects by targeting the cell membrane’s integrity, leading to increased permeability, loss of membrane potential, or catastrophic structural failure[2][4][8]. Antibiotics like daptomycin, polymyxin B, colistin, and nisin act via mechanisms that disrupt this integrity—generating pores, depolarizing the membrane, or interfering with membrane-specific protein complexes such as the BAM complex in Gram-negative bacteria[1][2][4]. Membrane-active agents are essential for treating persistent infections, especially those involving dormant cells less responsive to agents targeting biosynthetic pathways[3][4]. However, “Bacterial membrane integrity” lacks the specificity of a canonical molecular target (e.g., a defined protein, enzyme, or receptor), and thus is not catalogued as a standardized, name-based drug target. This introduces challenges in specificity, selectivity, and toxicity, as well as limited biomarker development for clinical monitoring[2][3][8]. Therefore, "Bacterial membrane integrity" is not a proper therapeutic target name, but rather a property or function susceptible to pharmacologic perturbation.

Disrupting membrane integrity via pore formation or detergent-like activity; Depolarizing the membrane to alter proton gradients; Binding and perturbing key membrane lipids (e.g., lipopolysaccharides, lipid II); Inhibiting outer membrane protein assembly complexes (e.g., BAM complex); Indirectly inhibiting biosynthetic processes via membrane disruption